Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

-Enrollment Continues to Progress in HOPE-3, the Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy ; On Track to Report Interim Analysis in Fourth Quarter of 2023- -Plan to... | May 11, 2023

Related Keywords

San Diego ,California ,United States ,Japan ,Joyce Allaire ,Linda Marb ,Raquel Cona ,Nasdaq ,Exosome Platform Technology ,Capricor Therapeutics Inc ,Twitter ,Nippon Shinyaku Co Ltd ,World Vaccine Congress ,Globenewswire Inc ,Facebook ,Capricor Company Contact ,Clinical Research Forum ,Duchenne Muscular Dystrophy Program ,Exchange Commission ,Lifesci Advisors ,Instagram ,Strategic Communications ,Top Ten Clinical Research Achievement Award ,Enrollment Continues ,Duchenne Muscular Dystrophy ,Report Interim Analysis ,Fourth Quarter ,Label Extension Data ,Second Quarter ,Webcast Today ,Recent Operational ,Muscular Dystrophy Program ,Parent Project Muscular Dystrophy ,Ten Clinical Research Achievement ,Microbiology Spectrum ,Vaccine Congress ,Nippon Shinyaku ,Japan Exclusive Commercialization ,Distribution Agreement ,Private Securities Litigation Reform Act ,Annual Report ,Investigational New Drug ,Media Contact ,Investor Contact ,Sci Advisors ,Company Contact ,Chief Financial ,Capricor Therapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,Ontinues ,O ,Progress ,N ,The ,Hase , ,Linical ,Trial ,F ,Muscular ,Dystrophy ,Track ,Report ,Interim ,Analysis ,Fourth ,Quarter ,F Capr Us14070b3096 ,